Former Ernst and Young
Senior Partner to serve as Chair of Audit Committee
BOSTON, Jan. 4, 2024
/PRNewswire/ -- Valo Health, Inc ("Valo"), a technology company
focused on utilizing large scale data and artificial intelligence
("AI") driven computation to discover and develop therapeutics,
today announced the appointment of Lisa P.
Young to its Board of Directors and as the chair of its
Audit Committee. Young is a seasoned board member and global
business leader with over 36 years of cross-sector, international
experience in public accounting and professional services.
"I am honored to welcome Lisa to the Valo Board of Directors.
Her nearly four decades at EY in working with new business models
and technology leaders across multiple industries have armed her
with the expertise to exceed in leading our Board's audit
committee," said Valo CEO and Founder, David Berry, PhD, MD. "Lisa brings a distinctive
skillset and shares in our philosophy that success starts with
culture. I am excited to partner with Lisa as we build the
next phase of Valo."
"I am thrilled to join Valo Health's board of directors and to
chair its audit committee," said Young. "I am inspired by Valo's
mission to develop better therapeutics for patients faster using
large scale human-centric data, and by the team that has come
together to bring this exciting vision to reality. I look forward
to applying what I've learned throughout my career to complement
the organization to future successes."
Young was with Ernst & Young LLP ("EY") for 36 years, with
24 of those years as a partner, and held several business
leadership and client serving roles including Senior Global Client
Service Partner, Americas Professional Practice Partner and Global
Capital Markets Partner in EY's national office. Young serves on
the Board of Directors of Accelus, Inc., a company focused on
minimally invasive spine surgery technology, and chairs their audit
and finance committee and is a member of the nominating and
corporate governance committee, and on the Board of Directors of
Textainer Group Holdings (NYSE: TGH) as a director and member of
their audit and risk committee and the compensation committee. She
serves as the Advancement Chair of the Board of Trustees for the
Columbus Museum of Art, a member and Finance Chair of the Board of
Directors of the Dallas Black Dance Theatre and for FringeArts in
Philadelphia, and a member of the
Texas Tech University Rawls College of
Business Advisory Council. Young holds a Bachelor of Business
Administration, Cum Laude, in Finance and Accounting from
Texas Tech University, and is a
certified public accountant.
About Valo Health
Valo Health, Inc is a
technology company focused on utilizing large scale data and
AI-driven computation to discover and develop therapeutics.
Valo aims to fully integrate human-centric data across the
entire drug development life cycle into a single unified
architecture, thereby accelerating the discovery and development of
life-changing drugs while simultaneously reducing costs, time, and
failure rates. The company's Opal Computational Platform™ is an
end-to-end drug discovery and development platform with a unified
architecture designed to transform data into valuable insights that
may accelerate discoveries and enable Valo to advance
a robust pipeline of programs, initially focused on cardiovascular
metabolic renal, oncology, and neurodegenerative
disease. Founded by Flagship Pioneering and headquartered in
Boston, MA, Valo also
has offices in Lexington, MA, and
New York, NY. To learn more,
visit valohealth.com.
Contacts
Media:
Kate
Clayton
kclayton@valohealth.com
Investors:
Graeme Bell
gbell@valohealth.com
View original
content:https://www.prnewswire.com/news-releases/lisa-p-young-appointed-to-valos-board-of-directors-302026455.html
SOURCE Valo Health, Inc.